Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1% Tavilermide · 1 trial · 1 indication
An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE)
A patient-reported subjective assessment of ocular discomfort recorded at each of the 5 office visits throughout the treatment period
| Arm | Type | Description |
|---|---|---|
| Tavilermide Ophthalmic Solution | ACTIVE_COMPARATOR | 1% Tavilermide Ophthalmic Solution |
| Vehicle Ophthalmic Solution | PLACEBO_COMPARATOR | Placebo Ophthalmic Solution |
| Name | Type | Description |
|---|---|---|
| 1% Tavilermide Ophthalmic Solution | DRUG | 1% Tavilermide BID Dosing |
| Placebo Ophthalmic Solution | DRUG | Vehicle Ophthalmic Solution |
Inclusion Criteria: * Be at least 18 years of age. * Provided written informed consent. * Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye Exclusion Criteria: * Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) at Visit 1. *...
1% Tavilermide is an investigational small molecule being studied for the treatment of Keratoconjunctivitis Sicca, commonly known as dry eye disease. It is formulated as an ophthalmic solution and is currently in Phase 3 clinical development. The drug is not yet approved and remains under investigation for this condition.
1% Tavilermide is a small molecule ophthalmic solution being developed for dry eye disease. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being evaluated for safety and efficacy in patients with Keratoconjunctivitis Sicca.
1% Tavilermide is being developed by BrainsWay Ltd., a company traded under the ticker symbol BWAY. The drug is in Phase 3 clinical development for the treatment of Keratoconjunctivitis Sicca, also known as dry eye disease. BrainsWay is conducting clinical trials to evaluate its safety and efficacy.
1% Tavilermide is in Phase 3 clinical development for the treatment of Keratoconjunctivitis Sicca, or dry eye disease. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 clinical trial has been completed to evaluate its safety and efficacy in this condition.
1% Tavilermide has one completed Phase 3 clinical trial registered under NCT02665234. This study, titled 'A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease,' enrolled 400 participants in the United States. The trial was randomized, double-blind, and placebo-controlled, and included biomarker-selected patients.
Yes, 1% Tavilermide is also known as MIM-D3. The clinical trial NCT02665234 refers to the drug as 'Tavilermide (MIM-D3) Ophthalmic Solution.' This alternative name may be used in scientific literature and clinical trial registrations for the same investigational treatment for dry eye disease.